![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ALS2CL |
Gene summary for ALS2CL |
![]() |
Gene information | Species | Human | Gene symbol | ALS2CL | Gene ID | 259173 |
Gene name | ALS2 C-terminal like | |
Gene Alias | RN49018 | |
Cytomap | 3p21.31 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | A0A024R2U1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
259173 | ALS2CL | HCC1_Meng | Human | Liver | HCC | 2.23e-03 | -6.64e-03 | 0.0246 |
259173 | ALS2CL | HCC2_Meng | Human | Liver | HCC | 1.38e-08 | 7.06e-02 | 0.0107 |
259173 | ALS2CL | HCC2 | Human | Liver | HCC | 2.74e-08 | 2.52e+00 | 0.5341 |
259173 | ALS2CL | S027 | Human | Liver | HCC | 1.31e-09 | 5.67e-01 | 0.2446 |
259173 | ALS2CL | S028 | Human | Liver | HCC | 3.22e-17 | 5.30e-01 | 0.2503 |
259173 | ALS2CL | S029 | Human | Liver | HCC | 1.83e-12 | 6.08e-01 | 0.2581 |
259173 | ALS2CL | C04 | Human | Oral cavity | OSCC | 2.50e-03 | 2.76e-01 | 0.2633 |
259173 | ALS2CL | C21 | Human | Oral cavity | OSCC | 3.06e-06 | 2.58e-01 | 0.2678 |
259173 | ALS2CL | C30 | Human | Oral cavity | OSCC | 1.28e-12 | 7.11e-01 | 0.3055 |
259173 | ALS2CL | C51 | Human | Oral cavity | OSCC | 2.58e-09 | 3.66e-01 | 0.2674 |
259173 | ALS2CL | C57 | Human | Oral cavity | OSCC | 8.11e-04 | 2.42e-01 | 0.1679 |
259173 | ALS2CL | C06 | Human | Oral cavity | OSCC | 3.71e-02 | 5.79e-01 | 0.2699 |
259173 | ALS2CL | SYSMH1 | Human | Oral cavity | OSCC | 9.73e-03 | 7.82e-02 | 0.1127 |
259173 | ALS2CL | SYSMH2 | Human | Oral cavity | OSCC | 1.32e-07 | 2.16e-01 | 0.2326 |
259173 | ALS2CL | SYSMH3 | Human | Oral cavity | OSCC | 9.89e-10 | 3.14e-01 | 0.2442 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605021 | Liver | HCC | vesicle organization | 194/7958 | 300/18723 | 5.58e-15 | 3.97e-13 | 194 |
GO:000703211 | Liver | HCC | endosome organization | 61/7958 | 82/18723 | 4.36e-09 | 1.15e-07 | 61 |
GO:00160508 | Oral cavity | OSCC | vesicle organization | 189/7305 | 300/18723 | 2.40e-17 | 2.14e-15 | 189 |
GO:00070327 | Oral cavity | OSCC | endosome organization | 59/7305 | 82/18723 | 1.41e-09 | 3.39e-08 | 59 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALS2CL | SNV | Missense_Mutation | c.1385A>G | p.His462Arg | p.H462R | Q60I27 | protein_coding | tolerated(0.08) | benign(0.078) | TCGA-BC-A112-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
ALS2CL | SNV | Missense_Mutation | c.14N>T | p.Glu5Val | p.E5V | Q60I27 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.941) | TCGA-MI-A75G-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ALS2CL | SNV | Missense_Mutation | novel | c.1232N>C | p.Cys411Ser | p.C411S | Q60I27 | protein_coding | tolerated(0.24) | benign(0.341) | TCGA-38-4631-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ALS2CL | SNV | Missense_Mutation | novel | c.8N>C | p.Asn3Thr | p.N3T | Q60I27 | protein_coding | tolerated_low_confidence(0.27) | benign(0) | TCGA-44-7669-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | alimta | PD |
ALS2CL | SNV | Missense_Mutation | c.2299N>T | p.Ser767Cys | p.S767C | Q60I27 | protein_coding | tolerated(0.18) | benign(0.007) | TCGA-50-6590-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | paclitaxel | CR | |
ALS2CL | SNV | Missense_Mutation | novel | c.1714G>A | p.Asp572Asn | p.D572N | Q60I27 | protein_coding | tolerated(0.64) | benign(0.017) | TCGA-55-A4DF-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ALS2CL | SNV | Missense_Mutation | c.2814G>C | p.Met938Ile | p.M938I | Q60I27 | protein_coding | tolerated(0.66) | benign(0.023) | TCGA-62-A46O-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ALS2CL | SNV | Missense_Mutation | rs138602401 | c.1879N>T | p.Val627Leu | p.V627L | Q60I27 | protein_coding | tolerated(0.1) | benign(0.054) | TCGA-69-7978-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ALS2CL | SNV | Missense_Mutation | c.2029N>T | p.Ala677Ser | p.A677S | Q60I27 | protein_coding | deleterious(0.05) | probably_damaging(0.994) | TCGA-78-7158-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
ALS2CL | SNV | Missense_Mutation | novel | c.2144N>T | p.Glu715Val | p.E715V | Q60I27 | protein_coding | deleterious(0.01) | possibly_damaging(0.601) | TCGA-21-1082-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |